人類生殖技術(Human Reproductive Technologies)：製品、市場、參與企業 -2005年版-

Abstract

In each of the three major areas of infertility, contraception and sexual dysfunction, there is increasing interest and advancements. One of the most widely publicized, celebrated and, at the time, controversial medical landmarks in this area was the use of assisted reproductive technology (ART) to manage infertility. Recent developments in the field of ART have intensified the hopes and wishes of infertile people to resolve their infertility.

New developments in the area of contraception have stepped up the quest for easier, safer and more convenient contraception methods. There is no miracle drug or contraception method but scientists are pursuing several avenues of discovery to create better options for individuals.

Sexual dysfunction now is an acknowledged disorder in the eyes of the general public and the medical community. Prior to the introduction of Viagra, the disorder was present but not acknowledged, and largely went untreated.

This BCC study presents a comprehensive, up-to-date look at the market for reproductive drugs and technologies. Markets are divided according to treatment type and indication. The products in some markets are mature, while those in other markets are just beginning to emerge. The competitive landscape is comprised of large, established pharmaceutical companies and many smaller developing companies. The reproductive health arena still is wide open in terms of competition because there still is a great need to provide products that are safe and effective.

SCOPE OF STUDY

The report contains:

• A review of male and female reproductive health
• An overview of standard pharmaceutical treatments, devices and technologies
• An analysis of market size in the categories of infertility, artificial reproductive technologies, fertility diagnostics, contraception and sexual dysfunction with forecasts to 2009
• Market participants and current competitor market shares
• An investigation of pipeline products and technologies.

Table of Contents

• INTRODUCTION
  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR STUDY
  • SCOPE OF STUDY
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ON-LINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Summary Figure: TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• INDUSTRY OVERVIEW
  • STRUCTURE AND FUNCTION OF THE REPRODUCTIVE SYSTEM
    • MALE
    • FEMALE
      • Female (Continued)
      • Female (Continued)
      • Female (Continued)
      • Neuroendocrine Regulation
      • Menarche
      • Menstruation Cycle
    • PHASES OF SEXUAL RESPONSES
  • Table 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
    • Male Sexual Response
    • Female Sexual Response
    • NEUROHORMONAL CONTROL OF THE FEMALE AND MALE REPRODUCTIVE SYSTEM
      • Estrogen
      • Progestogens
      • Testosterone
    • EFFECTS OF AGING
      • Effects of Aging (Continued)
    • ISSUES AND TRENDS OF REPRODUCTIVE HEALTH
      • CONTRACEPTIVE INSURANCE
      • LEGISLATIVE ACTIONS
        • Bioethics Commission
          • Bioethics Commission (Continued)
      • NEW USE FOR CONTRACEPTIVES
        • New Use for Contraceptives (Continued)
      • AGING AND INFERTILITY
      • DEATH BY CONTRACEPTIVE PATCH
      • SEXUAL DYSFUNCTION AND CANCER
      • INFERTILITY AND CANCER
        • Chemotherapy
        • Radiation
        • Prevention Strategies
        • Procreative Alternatives
          • Procreative Alternatives (Continued)
      • MARKETING TACTICS
      • MERCHANDIZING TARGETING WOMEN
      • COUNTERFEIT PRODUCTS
      • GENERIC PARTICIPATION
  • Table 2 PRESCRIPTION GENERIC DRUG APPROVALS BY COMPANY AND APPROVAL DATE 2003-2004
    • INTERNATIONAL ISSUES
    • SURPLUS EMBRYOS AND FETUSES
      • Surplus Embryos and Fetuses (Continued)
    • DESIGNER BABIES
      • Designer Babies (Continued)
    • STEM CELL AND OTHER CONTROVERSIAL ISSUES
      • Stem Cell and Other Controversial Issues (Continued)
      • Stem Cell and Other Controversial Issues (Continued)
    • CONTROVERSIAL DISPOSAL OF EMBRYOS
      • Controversial Disposal of Embryos (Continued)
    • DEMOGRAPHICS
  • Table 3 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
  • Figure 1 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
  • Table 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2003-2030 (THOUSANDS)
  • Figure 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030
  • Table 5 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND ESTIMATED 2005
  • Table 6 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980 TO 2000
  • Table 7 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
• INFERTILITY MARKET
  • INTRODUCTION AND OVERVIEW OF INFERTILITY
    • DEFINITION OF INFERTILITY
    • ETIOLOGY OF INFERTILITY
    • INCIDENCE AND PREVALENCE OF INFERTILITY
    • EVALUATION OF FERTILITY
      • Male Factor
        • Male Factor (Continued)
      • Artificial Insemination
        • Artificial Insemination (Continued)
        • Artificial Insemination (Continued)
      • Vaginal and Cervical Factors
      • Immunological Factors
      • Uterine and Tubal Factors
        • Uterine and Tubal Factors (Continued)
      • Ovarian Factors
    • UNEXPLAINED INFERTILITY
    • MULTIPLE BIRTHS
  • METHODS OF TREATMENT
    • FERTILITY PHARMACEUTICALS
      • Introduction and Types
        • Introduction and Types (Continued)
        • Antagon
        • Bravelle
        • Cetrotide
        • Clomid
          • Clomid (continued)
        • Crinone
        • Factrel
        • Fertinex
        • Follistim
        • Gonal-F
        • Humegon
        • Lupron
        • Novarel
        • Ovidrel
        • Parlodel
        • Pregnyl
        • Profasi
        • Prometrium
        • Repronex
        • Serophene
  • Table 8 PRESCRIPTION FERTILITY DRUGS
    • Market Revenues and Forecast
  • Table 9 MARKET SIZE OF U.S. INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 10 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 3 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • Future Advancements in Infertility Products
  • Table 11 INFERTILITY DRUGS IN DEVELOPMENT
    • ARTIFICIAL REPRODUCTIVE TECHNOLOGIES
      • Types
        • IVF
          • Ovulation Induction
          • Oocyte Retrieval
          • Fertilization
          • Embryo Transfer
          • Results of IVF
        • GIFT
        • ZIFT
        • Wombs for Rent
        • Oocyte Donation
        • Frozen Embryos
      • U.S. Fertility Clinics
  • Table 12 2001 NATIONAL SUMMARY OF ARTIFICIAL REPRODUCTIVE THERAPIES
  • Table 13 2001 NATIONAL ARTIFICIAL REPRODUCTIVE THERAPIES CYCLE PROFILE
  • Table 14 2001 PREGNANCY SUCCESS RATES
    • Market Revenues and Forecast
  • Table 15 MARKET SIZE OF U.S. ARTIFICIAL REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Future Trends in Artificial Reproductive Technology
      • Future Trends in Artificial (Continued)
      • Future Trends in Artificial (Continued)
    • FERTILITY DIAGNOSTICS
      • Types
        • Urine Studies
          • Pregnancy Testing
          • Ovulation Testing
          • Ovulation Testing (continued)
          • Sperm Testing
        • Hormone Studies
        • Blood Studies
      • Market Revenues and Forecast
  • Table 16 MARKET SIZE OF U.S. FERTILITY DIAGNOSTICS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 17 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 4 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • Future Advancements in Diagnostic Fertility Treatment
    • TOTAL INFERTILITY MARKET REVENUES AND FORECAST
  • Table 18 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 5 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• CONTRACEPTION MARKET
  • INTRODUCTION AND OVERVIEW OF CONTRACEPTION
    • INTRODUCTION AND(CONTINUED)
  • Table 19 CONTRACEPTIVE EFFECTIVENESS: THEORETICAL AND ACTUAL USE RATES
    • METHODS OF TREATMENT
      • PHARMACEUTICALS
        • Types
          • Oral Contraceptives
            • Oral Contraceptives (continued)
            • Oral Contraceptives (continued)
            • Oral Contraceptives (continued)
  • Table 20 MOST COMMONLY USED ORAL CONTRACEPTIVES, 2004
    • Alesse
    • Brevicon and Norinyl
    • Desogen
    • Estrostep
    • Levlen ED
    • Levora
    • Loestrin
    • LoOvral
    • Low-Ogestrel
    • Microgestin
    • Mircette
    • Necon
    • Nordette
    • Nor-QD
    • OrthoEvra
    • Ortho Micronor
    • Ortho TriCyclen
    • OrthoCept
    • Ovcon 35
    • Ovral
    • Seasonale
    • Tri-Levlen
    • Tri-Norinyl
    • Triphasil
    • Trivora
    • Yasmin 28
    • Zovia
  • Table 21 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
  • Table 21 (CONTINUED)
  • Table 22 PROGESTIN POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
  • Table 23 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
    • Other Drug Regimens for Contraception
      • Other Drug Regimens for (continued)
    • Market Revenues and Forecast
  • Table 24 MARKET SIZE OF U.S. CONTRACEPTIVE PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 25 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ Millions)
  • Figure 6 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • DEVICES
      • Introduction and Types
        • Intrauterine Devices
        • NuvaRing
      • Market Revenues and Forecast
  • Table 26 MARKET SIZE OF U.S. CONTRACEPTIVE DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 27 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 7 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • FUTURE ADVANCEMENTS IN CONTRACEPTION
  • Table 28 CONTRACEPTIVE DRUGS IN DEVELOPMENT
  • Table 28 (CONTINUED)
    • YASMIN 20
    • C31G (SAVVY)
    • IMPLANON
    • LIBREL
    • THE 7-DAY TRANSLUCENT CONTRACEPTIVE PATCH
    • TESTOSTERONE UNDECANOATE
    • IMMUNO-CONTRACEPTIVE VACCINE
    • ORG 33628
    • TANAPROGET
    • USHERCELL
    • INVISIBLE CONDOM
    • TOTAL MARKET REVENUES AND FORECAST
  • Table 29 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 8 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• SEXUAL DYSFUNCTION MARKET
  • INTRODUCTION AND OVERVIEW
    • TYPES OF SEXUAL DYSFUNCTION
    • CAUSES OF SEXUAL DYSFUNCTION
    • DEMOGRAPHICS OF SEXUAL DYSFUNCTION
  • METHODS OF TREATMENT
    • PHARMACEUTICALS
      • Introduction and Types
        • Viagra
        • Cialis
        • Levitra
        • Uprima
        • Vasomax
        • Yohimbine
        • Caverject
        • MUSE
      • Market Revenues and Forecast
  • Table 30 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 31 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 9 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • DEVICES
      • Introduction and Types
        • V.E.T. System and Assist
        • Erectaid Classic System
        • Imaging Agents
      • Market Revenues and Forecast
  • Table 32 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
    • Competitive Analysis
  • Table 33 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
  • Figure 10 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
    • FUTURE ADVANCEMENTS IN SEXUAL DYSFUNCTION
      • FUTURE ADVANCEMENTS IN(CONTINUED)
  • Table 34 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
  • Table 34 (CONTINUED)
    • ALPROX-TD
    • INTRINSA
    • ABT-724
    • ALISTA
    • TESTOSTERONE MDTS
    • APOMORPHINE
    • FEMPROX
    • LIBIGEL
    • PT-141
    • TA-1970
    • TESTOSTERONE VAGINAL RING
    • TOPIGLAN
    • TOSTRELLE
    • TOTAL MARKET REVENUES AND FORECAST
  • Table 35 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 11 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• PATENTS
  • PATENT ANALYSIS BY MANUFACTURER
  • Table 36 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
    • PATENTS BY APPLICATION
      • INFERTILITY TREATMENTS
      • CONTRACEPTION
      • SEXUAL DYSFUNCTION
    • LEADING MARKET MANUFACTURERS
  • Table 37 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT
• TOTAL MARKET
  • TOTAL MARKET SIZE BY CATEGORY
  • Table 38 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 12 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
  • Table 39 TOTAL REVENUES, MARKET SHARE, AND NUMBER OF MANUFACTURERS OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2004 ($ MILLIONS)
  • Figure 13 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2004 (%)
  • Figure 14 U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY MARKET SEGMENT, 2004 (%)
    • INDUSTRY PARTICIPANTS BY CATEGORY
  • Table 40 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
  • Table 40 (CONTINUED)
    • TOTAL MARKET SIZE BY PRODUCT TYPE
  • Table 41 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
  • Figure 15 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• APPENDIX
  • SELECTED LIST OF US FERTILITY CLINICS
    • ALABAMA
    • ARIZONA
    • CALIFORNIA
    • COLORADO
    • CONNECTICUT
    • DISTRICT OF COLUMBIA
    • FLORIDA
    • GEORGIA
    • IDAHO
    • ILLINOIS
    • INDIANA
    • KANSAS
    • MAINE
    • MARYLAND
    • MASSACHUSETTS
    • MICHIGAN
    • MINNESOTA
    • MONTANA
    • NEVADA
    • NEW HAMPSHIRE
    • NEW JERSEY
    • NEW YORK
    • NORTH CAROLINA
    • OREGON
    • RHODE ISLAND
    • SOUTH CAROLINA
    • SOUTH DAKOTA
    • TEXAS
    • VIRGINIA
    • UTAH
    • WASHINGTON
  • COMPANY PROFILES
    • BAYER AG
    • BERLEX LABORATORIES, INC.
    • BRISTOL-MYERS SQUIBB CO.
    • CHURCH & DWIGHT COMPANY, INC.
    • ELI LILLY & CO.
    • ENDOCARE, INC.
    • GLAXOSMITHKLINE PLC
    • ICOS CORP.
    • NOVARTIS INTERNATIONAL AG
    • ORGANON INTERNATIONAL, INC.
    • ORTHO-MCNEIL PHARMACEUTICAL, INC.
    • PFIZER, INC.
    • PRINCETON BIOMEDITECH CORP.
    • SERONO S.A.
    • TAP PHARMACEUTICAL PRODUCTS, INC.
    • VIVUS, INC.
    • WATSON PHARMACEUTICALS, INC.
    • WYETH
  • LIST OF COMPANIES
  • Table 42 LIST OF COMPANIES
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
  • Table 42 (CONTINUED)
• Summary Table:
• Table 1 STRUCTURAL HOMOLOGUES OF THE MALE AND FEMALE REPRODUCTIVE SYSTEMS
• Table 2 PRESCRIPTION GENERIC DRUG APPROVALS BY COMPANY AND APPROVAL DATE 2003-2004
• Table 3 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
• Table 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2003-2030 (THOUSANDS)
• Table 5 CHARACTERISTICS OF WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR: 2000 AND ESTIMATED 2005
• Table 6 WOMEN WHO HAVE HAD A CHILD IN THE LAST YEAR BY AGE AND LABOR FORCE STATUS: 1980 TO 2000
• Table 7 ESTIMATED CONTRACEPTIVE USE BY TYPE BY AGE, ETHNIC GROUP AND MARITAL STATUS (%)
• Table 8 PRESCRIPTION FERTILITY DRUGS
• Table 9 MARKET SIZE OF U.S. INFERTILITY PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 10 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 11 INFERTILITY DRUGS IN DEVELOPMENT
• Table 12 2001 NATIONAL SUMMARY OF ARTIFICIAL REPRODUCTIVE THERAPIES
• Table 13 2001 NATIONAL ARTIFICIAL REPRODUCTIVE THERAPIES CYCLE PROFILE
• Table 14 2001 PREGNANCY SUCCESS RATES
• Table 15 MARKET SIZE OF U.S. ARTIFICIAL REPRODUCTIVE TECHNOLOGIES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 16 MARKET SIZE OF U.S. FERTILITY DIAGNOSTICS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 17 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 18 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 19 CONTRACEPTIVE EFFECTIVENESS: THEORETICAL AND ACTUAL USE RATES
• Table 20 MOST COMMONLY USED ORAL CONTRACEPTIVES, 2004
• Table 21 ESTROGEN AND PROGESTIN HORMONE DOSES IN COMBINED BIRTH CONTROL PILLS
• Table 22 PROGESTIN POTENCY OF DIFFERENT ORAL CONTRACEPTIVE PROGESTINS
• Table 23 CURRENT PILL PROBLEMS AND CHOICE OF PILL TO SWITCH TO
• Table 24 MARKET SIZE OF U.S. CONTRACEPTIVE PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 25 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ Millions)
• Table 26 MARKET SIZE OF U.S. CONTRACEPTIVE DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 27 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 28 CONTRACEPTIVE DRUGS IN DEVELOPMENT
• Table 29 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 30 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION PHARMACEUTICALS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 31 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 32 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION DEVICES AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 33 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 ($ MILLIONS)
• Table 34 SEXUAL DYSFUNCTION DRUGS IN DEVELOPMENT
• Table 35 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 36 SELECTED MANUFACTURER PATENTS FOR REPRODUCTIVE PRODUCTS AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT
• Table 37 PATENT ANALYSIS BY SELECTED LEADING REPRODUCTIVE TREATMENT MANUFACTURERS, 1976-PRESENT
• Table 38 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 39 TOTAL REVENUES, MARKET SHARE, AND NUMBER OF MANUFACTURERS OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY MARKET SEGMENT, 2004 ($ MILLIONS)
• Table 40 REPRODUCTIVE INDUSTRY PARTICIPANTS BY PRODUCT CATEGORY
• Table 41 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, THROUGH 2009 ($ MILLIONS)
• Table 42 LIST OF COMPANIES
• Summary Figure:
• Figure 1 U.S. LIVE BIRTH RATES, 1960-2004 (THOUSANDS)
• Figure 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2003-2030
• Figure 3 INFERTILITY PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 4 FERTILITY DIAGNOSTIC MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 5 MARKET SIZE OF U.S. INFERTILITY TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 6 CONTRACEPTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 7 CONTRACEPTIVE DEVICE MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 8 MARKET SIZE OF U.S. CONTRACEPTIVE PRODUCTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 9 SEXUAL DYSFUNCTION PHARMACEUTICAL MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 10 SEXUAL DYSFUNCTION DEVICES MANUFACTURER MARKET SHARE BY REVENUES, 2004 (%)
• Figure 11 MARKET SIZE OF U.S. SEXUAL DYSFUNCTION TREATMENTS AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 12 TOTAL REVENUES OF U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS BY CATEGORY AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)
• Figure 13 NUMBER OF SELECTED MANUFACTURERS BY MARKET SEGMENT, 2004 (%)
• Figure 14 U.S. REPRODUCTIVE TECHNOLOGIES AND PRODUCTS MARKET SHARE BY MARKET SEGMENT, 2004 (%)
• Figure 15 TOTAL REVENUES OF U.S. REPRODUCTION PRODUCTS BY TYPE AT U.S. MANUFACTURERS SALES LEVELS, 2002-2009 ($ MILLIONS)